| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439390 | European Journal of Cancer | 2018 | 9 Pages |
Abstract
Normal IADL score was associated with a good efficacy and safety of both BEV and CT. Köhne criteria may be relevant prognostic factors in older patients. Adding bevacizumab to chemotherapy does not impair patient autonomy or QoL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
T. Aparicio, O. Bouché, E. Francois, F. Retornaz, E. Barbier, J. Taieb, S. Kirscher, P.-L. Etienne, R. Faroux, F. Khemissa Akouz, F. El Hajbi, C. Locher, Y. Rinaldi, T. Lecomte, S. Lavau-Denes, M. Baconnier, A. Oden-Gangloff, D. Genet, Fabien Subtil,